shutterstock_1686828337_arrowsmith2
arrowsmith2 / Shutterstock.com
13 October 2022Big PharmaSarah Speight

In conversation with...Beatriz San Martin, Arnold & Porter

The scientist-turned IP specialist chats to LSIPR about why she ‘loves’ the IP sector, her views on policy and funding in science and research, and the cases she’s most proud of.

While Beatriz San Martin began her career in academic research, she soon followed a path that would eventually lead her to intellectual property law.

Her academic career is no small thing though. San Martin was a scientist with a degree and a Wellcome Trust PhD and postdoc from the University of Cambridge specialising in genetics, cellular and molecular biology.

But an interest in scientific policymaking led to an interest in the IP sector and she is currently a partner with Arnold & Porter in London.

More than 20 years on, her practice encompasses not only life sciences, but also innovative technologies. For example, she is currently working on complex database rights infringement proceedings involving multiple claimants, defendants and counterparty defendants, Genius Sports Technologies & Ors v Soft Construct (Malta) & Ors.

San Martin has built up an impressive body of experience that includes handling cases before the UK Courts and the Court of Justice of the European Union ( CJEU) and specialising in supplementary protection certificates (SPCs).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
10 July 2020   The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
Biotechnology
20 January 2022   While the effort to secure greater vaccine and treatment equality via an IP waiver is admirable, it could stifle innovation and create long-term problems, say Matthew Howell and Lauren Griffin of Alston & Bird.

More on this story

Generics
10 July 2020   The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
Biotechnology
20 January 2022   While the effort to secure greater vaccine and treatment equality via an IP waiver is admirable, it could stifle innovation and create long-term problems, say Matthew Howell and Lauren Griffin of Alston & Bird.

More on this story

Generics
10 July 2020   The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
Biotechnology
20 January 2022   While the effort to secure greater vaccine and treatment equality via an IP waiver is admirable, it could stifle innovation and create long-term problems, say Matthew Howell and Lauren Griffin of Alston & Bird.